TY - JOUR
T1 - Extracellular cathepsin K exerts antimicrobial activity and is protective against chronic intestinal inflammation in mice
AU - Sina, Christian
AU - Lipinski, Simone
AU - Gavrilova, Olga
AU - Aden, Konrad
AU - Rehman, Ateequr
AU - Till, Andreas
AU - Rittger, Andrea
AU - Podschun, Rainer
AU - Meyer-Hoffert, Ulf
AU - Haesler, Robert
AU - Midtling, Emilie
AU - Pütsep, Katrin
AU - McGuckin, Michael A.
AU - Schreiber, Stefan
AU - Saftig, Paul
AU - Rosenstiel, Philip
PY - 2013/4/1
Y1 - 2013/4/1
N2 - Objective: Cathepsin K is a lysosomal cysteine protease that has pleiotropic roles in bone resorption, arthritis, atherosclerosis, blood pressure regulation, obesity and cancer. Recently, it was demonstrated that cathepsin K-deficient (Ctsk-/-) mice are less susceptible to experimental autoimmune arthritis and encephalomyelitis, which implies a functional role for cathepsin K in chronic inflammatory responses. Here, the authors address the relevance of cathepsin K in the intestinal immune response during chronic intestinal inflammation. Design: Chronic colitis was induced by administration of 2% dextran sodium sulphate (DSS) in distilled water. Mice were assessed for disease severity, histopathology and endoscopic appearance. Furthermore, DSS-exposed Ctsk-/- mice were treated by rectal administration of recombinant cathepsin K. Intestinal microflora was assessed by real-time PCR and 16srDNA molecular fingerprinting of ileal and colonic mucosal and faecal samples. Results: Using Ctsk-/- mice, the authors demonstrate a protective role of cathepsin K against chronic DSS colitis. Dissecting the underlying mechanisms the authors found cathepsin K to be present in intestinal goblet cells and the mucin layer. Furthermore, a direct cathepsin K-mediated bactericidal activity against intestinal bacteria was demonstrated, which potentially explains the alteration of intestinal microbiota observed in Ctsk-/- mice. Rectal administration of recombinant cathepsin K in DSS-treated Ctsk-/- mice ameliorates the severity of intestinal inflammation. Conclusion: These data identify extracellular cathepsin K as an intestinal antibacterial factor with antiinflammatory potential and suggest that topical administration of cathepsin K might provide a therapeutic option for patients with inflammatory bowel disease.
AB - Objective: Cathepsin K is a lysosomal cysteine protease that has pleiotropic roles in bone resorption, arthritis, atherosclerosis, blood pressure regulation, obesity and cancer. Recently, it was demonstrated that cathepsin K-deficient (Ctsk-/-) mice are less susceptible to experimental autoimmune arthritis and encephalomyelitis, which implies a functional role for cathepsin K in chronic inflammatory responses. Here, the authors address the relevance of cathepsin K in the intestinal immune response during chronic intestinal inflammation. Design: Chronic colitis was induced by administration of 2% dextran sodium sulphate (DSS) in distilled water. Mice were assessed for disease severity, histopathology and endoscopic appearance. Furthermore, DSS-exposed Ctsk-/- mice were treated by rectal administration of recombinant cathepsin K. Intestinal microflora was assessed by real-time PCR and 16srDNA molecular fingerprinting of ileal and colonic mucosal and faecal samples. Results: Using Ctsk-/- mice, the authors demonstrate a protective role of cathepsin K against chronic DSS colitis. Dissecting the underlying mechanisms the authors found cathepsin K to be present in intestinal goblet cells and the mucin layer. Furthermore, a direct cathepsin K-mediated bactericidal activity against intestinal bacteria was demonstrated, which potentially explains the alteration of intestinal microbiota observed in Ctsk-/- mice. Rectal administration of recombinant cathepsin K in DSS-treated Ctsk-/- mice ameliorates the severity of intestinal inflammation. Conclusion: These data identify extracellular cathepsin K as an intestinal antibacterial factor with antiinflammatory potential and suggest that topical administration of cathepsin K might provide a therapeutic option for patients with inflammatory bowel disease.
UR - http://www.scopus.com/inward/record.url?scp=84874661796&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2011-300076
DO - 10.1136/gutjnl-2011-300076
M3 - Journal articles
C2 - 22442160
AN - SCOPUS:84874661796
SN - 0017-5749
VL - 62
SP - 520
EP - 530
JO - Gut
JF - Gut
IS - 4
ER -